

Nr Book	Presenter / 1st Author NAME	Presenter / 1st Author COUNTRY	Presentation / Abstract Title	
1	June, Carl	United States	Next generation CAR T cells for lymphoma and beyond	Oral Presentation
2	Melnick, Ari	United States	Precision Epigenetic Therapy for B-cell Lymphoma	Oral Presentation
3	Gaulard, Philippe	France	Thirty years of T-cell lymphomas	Oral Presentation
4	Rushton, Christopher	Canada	Identifying Mutations Enriched in Relapsed-Refractory DLBCL to Derive Genetic Factors Underlying Treatment Resistance	Oral Presentation
5	Vitolo, Umberto	Italy	ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R ² -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma	Oral Presentation
6	Nowakowski, Grzegorz	United States	ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP	Oral Presentation
7	Langerbeins, Petra	Germany	Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 trial	Oral Presentation
8	Singh, Ankur	United States	Designer Organoids for Modeling Epigenetics and Co-operative Signaling in Lymphoma	Oral Presentation
9	Louissaint, Abner	United States	MOUSE PDX AS NON-CLINICAL MODELS FOR LYMPHOMA	Oral Presentation
10	Aresu, Luca	Italy	Advancing our understanding and treatment of lymphoma with spontaneous canine models	Oral Presentation
11	Jain, Preetesh	United States	Combination of ibrutinib with rituximab (IR) is highly effective in previously untreated elderly (>65 years) patients (pts) with mantle cell lymphoma (MCL) – phase II trial	Oral Presentation
12	Wang, Michael	United States	Ibrutinib with rituximab (IR) and short course R-HyperCVAD/MTX is very efficacious in previously untreated young pts with mantle cell lymphoma (MCL)	Oral Presentation
13	Zoellner, Anna-Katharina	Germany	Autologous stem cell transplantation in first remission significantly prolongs progression-free and overall survival in mantle cell lymphoma	Oral Presentation
14	Le Gouill, Steven	France	Obinutuzumab plus DHAP followed by autologous stem cell transplantation (ASCT) plus Obinutuzumab maintenance provides a high MRD response rate in untreated MCL patients, results of LYMA-101 trial, a LYSA group study	Oral Presentation
15	Song, Yuqin	China	Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma	Oral Presentation
16	Visco, Carlo	Italy	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study	Oral Presentation
17	Donati, Benedetta	Italy	A gene expression-based score to predict interim PET positivity in Hodgkin lymphoma patients treated with ABVD.	Oral Presentation

18	Novo, Mattia	United States	Persistent mediastinal positron emission tomography (PET)-positivity after frontline therapy for Hodgkin Lymphoma is best managed by close observation	Oral Presentation
19	Vercellino, Laetitia	France	High Total Metabolic Tumor Volume at Baseline allows to discriminate for survival patients in response after R-CHOP : an ancillary analysis of the REMARC Study	Oral Presentation
20	Trněný, Marek	Czech Republic	Baseline total metabolic tumour volume is highly prognostic for refractoriness to immunochemotherapy in DLBCL: an analysis of the phase 3 GOYA trial	Oral Presentation
21	Chauvie, Stephane	Italy	Radiomics increase the prognostic value of clinical and PET risk factors in DLBCL: results from the phase 3 GOYA study	Oral Presentation
22	Strati, Paolo	United States	Prognostic Value of Pre-Treatment PET Scan in Patients with Follicular Lymphoma Receiving Frontline Therapy	Oral Presentation
23	Carr, Robert	United Kingdom	Non-Hodgkin Lymphoma in Adolescent and Young Adults - A National Prospective Population-based Study	Oral Presentation
24	Flerlage, Jamie	United States	Inclusion of a Pediatric Perspective into Recommendations for the Initial Evaluation and Staging of Hodgkin Lymphoma: A call to action from the International SEARCH Working	Oral Presentation
25	Flerlage, Jamie	United States	Safety and response after 2 cycles of Brentuximab vedotin substituting vincristine in the OEPA/COPDac regimen for HIGH Risk Pediatric Hodgkin Lymphoma (HL)	Oral Presentation
26	Kelly, Kara	United States	Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: CheckMate 744 Subgroup Analyses	Oral Presentation
27	Burke, Amos	United Kingdom	Ibrutinib + Chemoimmunotherapy (CIT) for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children (SPARKLE Trial): Initial Safety, PK, and Efficacy	Oral Presentation
28	Zhang, Wen	China	Chimeric antigen receptor T-cells (CAR-T) for refractory and relapsed Burkitt's lymphoma, early response in pediatric patients	Oral Presentation
29	Rogers, Kerry	United States	Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia	Oral Presentation
30	Smith, Stephen	United States	Rapid and Durable Responses With the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma—Alone or in Combination With Rituximab	Oral Presentation
31	Kalakonda, Nagesh	United Kingdom	A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	Oral Presentation
32	Witzig, Thomas	United States	Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from a Phase 2 Study	Oral Presentation

33	Horwitz, Steven	United States	Duvelisib, an oral dual PI3K- δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T-cell lymphoma: rationale for the phase 2 PRIMO trial	Oral Presentation
34	Scarisbrick, Julia	United Kingdom	Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: results from the MAAVORIC study	Oral Presentation
OT01	Pettitt, Andrew	United Kingdom	NCRI PETReA trial: a phase 3 evaluation of PET-guided, response-adapted therapy in patients with previously untreated, advanced-stage, high-tumour-burden follicular lymphoma	Oral Presentation
OT02	Tilly, Herve	France	POLARIX: a phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL	Oral Presentation
OT03	Xie, Yan	China	Phase III Randomized Study of Enzastaurin/R-CHOP Vs Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Genomic Biomarker DGM1 (ENGINE Study)	Oral Presentation
OT04	Villasboas, Jose	United States	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 trial of Varlilumab plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas	Oral Presentation
OT05	Cummin, Thomas	United Kingdom	ACCEPT: A Phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with Diffuse Large B-cell Lymphoma (DLBCL)	Oral Presentation
OT06	Porcu, Pierluigi	United States	TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy: An open label, multi-cohort, multi-center, international phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma	Oral Presentation
35	Knittel, Gero	Germany	An autochthonous mouse model of MYD88 p.L265P- and BCL2-driven diffuse large B cell lymphoma	Oral Presentation
36	Hilton, Laura	Canada	Cryptic <i>MYC</i> and <i>BCL2</i> rearrangements are among a range of genetic mechanisms underlying the double hit signature in non-double hit diffuse large B-cell lymphoma	Oral Presentation
37	Arthur, Sarah	Canada	Functional Characterization of <i>NFKB1Z</i> 3' UTR Mutations in Diffuse Large B-Cell Lymphoma	Oral Presentation
38	Sartori, Giulio	Switzerland	The transcription factor FLI1 sustains relevant biological pathways and drives oncogenes that promote cell growth in Diffuse Large B-Cell Lymphoma (DLBCL)	Oral Presentation
39	Roider, Tobias	Germany	Transcriptional and genomic intra-tumor heterogeneity drives subclone specific drug responses in diffuse large B cell lymphoma	Oral Presentation
40	Napoli, Sara	Switzerland	The noncoding RNA GEPCAR is involved in Wnt signaling and has tumor-suppressor activity in diffuse large B cell lymphoma	Oral Presentation

41	Ceriani, Luca	Switzerland	Integration between Metabolic Tumour Volume and Metabolic Heterogeneity Predicts Outcome of DLBCL Lymphoma Patients in the SAKK 38/07 Study Cohort	Oral Presentation
42	Westin, Jason	United States	Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone Prior to Combination With Chemotherapy For Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	Oral Presentation
43	Lugtenburg, Pieternella	Netherlands	Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: results from a randomized HOVON-Nordic Lymphoma Group phase III study	Oral Presentation
44	Shree, Tanaya	United States	Impaired Immune Health in Survivors of Diffuse Large B-cell Lymphoma (DLBCL): A Large Population-Based Study	Oral Presentation
45	Condoluci, Adalgisa	Switzerland	International Prognostic Score for Early Stage Chronic Lymphocytic Leukemia (IPS-A)	Oral Presentation
46	Fischer, Kirsten	Germany	Fixed-duration venetoclax plus obinutuzumab improves PFS and minimal residual disease negativity in patients with previously untreated CLL and comorbidities	Oral Presentation
47	Tausch, Eugen	Germany	Genetic markers and outcome in the CLL14 trial of the GCLLSG comparing front line obinutuzumab plus chlorambucil or venetoclax in patients with comorbidity	Oral Presentation
48	Ghia, Paolo	Italy	Acalabrutinib vs Rituximab Plus Idelalisib (IR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study	Oral Presentation
49	Xu, Wei	China	Zanubrutinib for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia	Oral Presentation
50	Mato, Anthony	United States	A Phase 2 Study to Assess the Safety and Efficacy of umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy	Oral Presentation
51	Advani, Ranjana	United States	The first-in-class anti-CD47 antibody Hu5F9-G4 + rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: Interim Phase 1b/2 results	Oral Presentation
52	Topp, Max	Germany	Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab) in Patients (Pts) with (w/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)	Oral Presentation
53	Dickinson, Michael	Australia	CD20-TCB (RG6026), a Novel "2:1" Format T-cell-engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	Oral Presentation
54	Radford, John	United Kingdom	Analysis of Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Oral Presentation
55	Collins, Graham	United Kingdom	Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT-301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)	Oral Presentation
56	Ghione, Paola	United States	Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed after receiving textured breast implants.	Oral Presentation

57	Lopez-Parra, Miriam	Spain	Autologous Stem Cell Transplantation as part of first-line therapy in patients with Peripheral T-cell Lymphoma: A multicenter GELTAMO/FIL study	Oral Presentation
58	Tournilhac, Olivier	France	First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation - FINAL results of the AATT study.	Oral Presentation
59	Qi, Shunan	China	Treatment benefit associating with non-anthracycline chemotherapy in Extranodal NK/T-cell lymphoma, nasal type	Oral Presentation
60	Tao, Rong	China	Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4)	Oral Presentation
61	Tedeschi, Alessandra	Italy	Five-Year Follow-Up of First-Line Ibrutinib for Treatment of Patients With Chronic Lymphocytic Leukemia//Small Lymphocytic Lymphoma	Oral Presentation
62	Al-Sawaf, Othman	Germany	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype (CKT) and chronic lymphocytic leukemia (CLL): A prospective analysis from the CLL14 trial	Oral Presentation
63	Wu, Jenny	United States	Impact of major genomic alterations on outcome of relapsed/refractory chronic lymphocytic leukemia patients receiving venetoclax plus rituximab in the phase 3 MURANO study	Oral Presentation
64	Handunnetti, Sasanka	Australia	An undetectable PB MRD status should be the therapeutic goal with venetoclax therapy in relapsed/ refractory CLL	Oral Presentation
65	Siddiqi, Tanya	United States	TRANSCEND CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Oral Presentation
66	Tiacci, Enrico	Italy	THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL	Oral Presentation
67	Moccia, Alden	Switzerland	Predictive value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).	Oral Presentation
68	Morschhauser, Franck	France	Efficacy and safety of obinutuzumab + lenalidomide + atezolizumab in patients with relapsed or refractory follicular lymphoma: primary analysis of a phase 1B/2 trial	Oral Presentation
69	Leonard, John P.	United States	AUGMENT phase III study: Lenalidomide/rituximab (R ²) improved efficacy over rituximab/placebo in relapsed/refractory follicular patients irrespective of POD24 status	Oral Presentation
70	Sharman, Jeff	United States	Interim analysis of phase IIIb MAGNIFY study of induction R ² followed by maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma	Oral Presentation
71	Delfau-Larue, Marie	France	Rituximab plus Lenalidomide is as effective as immunochemotherapy in the eradication of molecular disease in untreated Follicular Lymphoma: RELEVANCE LYSA ancillary Study	Oral Presentation

72	Stathis, Anastasios	Switzerland	SAKK 35/15: A phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients.	Oral Presentation
73	Mato, Anthony	United States	Phase I/II Study of umbralisib (TGR-1202) in Combination with ublituximab (TG-1101) and pembrolizumab in Patients with Rel/Ref CLL and Richter's Transformation	Oral Presentation
74	Smith, Stephen	United States	Pembrolizumab with RCHOP in Previously Untreated Diffuse Large B-Cell and Grade 3b Follicular Lymphoma: Final Results of a Phase I Trial	Oral Presentation
75	Tam, Constantine	Australia	Zanubrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory (R/R) follicular lymphoma (FL)	Oral Presentation
76	Shree, Tanaya	United States	A Phase I/II Trial of Ibrutinib, Intratumoral CpG and Local Radiation in Patients with Low-Grade B-Cell Lymphoma: Interim Clinical and Correlative Results	Oral Presentation
77	Diefenbach, Catherine	United States	Extended Follow-Up of a Phase I Trial of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412)	Oral Presentation
78	Cummin, Thomas	United Kingdom	High expression of BCL-2 and BCL-XL in diffuse large B-cell lymphoma confer poor prognosis but may be reversible by combined inhibition with BET inhibitors and BH3 mimetics.	Oral Presentation
79	Liu, Yuxuan	United States	First-in-Class HAT activator highly synergistic with pan-HDAC inhibitor romidepsin leading to profound histone acetylation cytotoxicity	Oral Presentation
80	Zhang, Rongjia	United States	Copanlisib and Volasertib overcome ibrutinib-venetoclax resistance via targeting PI3K-AKT signaling and G2/M cell cycle transition in mantle cell lymphoma	Oral Presentation
81	Zenz, Thorsten	Switzerland	The landscape of drug perturbation effects in leukemia and lymphoma	Oral Presentation
82	Philippaer, Ulrike	Belgium	Discovery of a novel, potential first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas	Oral Presentation
83	Kelleher, Joseph	United States	KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition	Oral Presentation
84	Tarantelli, Chiara	Switzerland	The antibody-drug conjugate (ADC) loncastuximab tesirine (ADCT-402) targeting CD19 shows strong <i>in vitro</i> anti-lymphoma activity both as single agents and in combination	Oral Presentation
85	Gandhi, Maher	Australia	EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3 rd Party EBV-specific CTL and ibrutinib therapy	Oral Presentation
86	Leppä, Sirpa	Finland	Young high risk patients with diffuse large B-cell lymphoma including <i>BCL-2/MYC</i> double hit lymphomas benefit from dose-dense immunochemotherapy with early CNS prophylaxis	Oral Presentation

87	Nowakowski, Grzegorz	United States	Safety and Efficacy of the PD-L1 Inhibitor Durvalumab With R-CHOP or R ² -CHOP in Subjects With Previously Untreated, High-Risk DLBCL	Oral Presentation
88	Davids, Matthew	United States	Initial Results of a Multicenter Phase 2 Study of Venetoclax in Combination with Dose-Adjusted R-EPOCH for Patients with Richter's Syndrome (CRC-043)	Oral Presentation
89	Morschhauser, Franck	France	Improved outcomes in patients (pts) with BCL2-positive diffuse large B-cell lymphoma (DLBCL) treated with venetoclax (Ven) plus R-CHOP: Results from the phase 2 CAVALLI study	Oral Presentation
90	Chong, Elise	United States	CD19-directed CAR T cell therapy (CTL019) for relapsed/refractory diffuse large B-cell and follicular lymphomas: Four year outcomes	Oral Presentation
91	Brousset, Pierre	France	Diagnosis and classification assistance from lymphoma microscopic images using deep learning	Oral Presentation
92	Pileri, Stefano	Italy	Integrating tumor- and microenvironment-reflecting genes in a unique and routine-applicable assay for accurate risk prediction in DLBCL.	Oral Presentation
93	Balasubramanian, Sriram	United States	Concordance Between Immunohistochemistry and Gene Expression Profiling Subtyping for Diffuse Large B-Cell Lymphoma in the Phase 3 PHOENIX Trial	Oral Presentation
94	Araf, Shamzah	United Kingdom	Longitudinal analyses of diagnostic-relapse biopsies of Diffuse Large B Cell Lymphoma suggest that relapse is mediated by distinct mechanisms in ABC and GCB lymphoma.	Oral Presentation
95	Barrans, Sharon	United Kingdom	Defining Burkitt-like lymphoma with 11q aberration in a specialised UK haematopathology diagnostic service	Oral Presentation
96	Quintanilla-Martinez de Fend, Leticia	Germany	Genome wide-analysis of t(14;18)-negative Follicular Lymphoma	Oral Presentation
97	Binkley, Michael	United States	Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma in the Modern Era: a Multi-institutional Experience of Adult Patients by ILROG	Oral Presentation
98	Ansell, Stephen	United States	Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma: CheckMate 205 Cohort D 2-Year Follow-Up	Oral Presentation
99	Gallamini, Andrea	France	Consolidation Radiotherapy could be omitted in advanced Hodgkin Lymphoma with large nodal mass in Complete Metabolic Response after ABVD. Final analysis of the randomized HD0607 trial.	Oral Presentation
100	Prica, Anca	Canada	Cost-effectiveness and cost-utility analysis of multiple treatment strategies using ABVD and/or BEACOPP in the treatment of advanced-stage Hodgkin lymphoma	Oral Presentation
101	Menter, Thomas	Switzerland	Prognostic implications of the microenvironment in follicular lymphoma under rituximab and rituximab+lenalidomide therapy; a translational study of the SAKK35/10 Trial	Oral Presentation

102	Perez Galan, Patricia	Spain	Deciphering the contribution of macrophages to follicular lymphoma pathogenesis: new insights into therapy	Oral Presentation
103	Batlevi, Connie	United States	Impact of PET Imaging and Histologic Transformation on the Prognosis of Early Disease Progression in Follicular Lymphoma	Oral Presentation
104	Federico, Massimo	Italy	Response oriented maintenance therapy in advanced Follicular Lymphoma. Results of the interim analysis of the FOLL12 trial conducted by the Fondazione Italiana Linfomi.	Oral Presentation
105	Morschhauser, Franck	France	INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA	Oral Presentation
106	Mottok, Anja	Germany	Integrative genomic analysis identifies key pathogenic concepts in primary mediastinal large B-cell lymphoma	Oral Presentation
107	Hayden, Anna	Canada	Outcome of Primary Mediastinal Large B-cell Lymphoma in the Rituximab era: Impact of a PET-guided Approach	Oral Presentation
108	Zinzani, Pier Luigi	Italy	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study	Oral Presentation
109	Ferreri, Andrés	Italy	R-CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL	Oral Presentation
110	Jagadeesh, Deepa	United States	Post-Transplant Lymphoproliferative Disorder (PTLD) After Solid Organ Transplant (SOT): Survival and Prognostication Among 570 Patients (pts) Treated in the Modern Era	Oral Presentation
111	Song, Yuqin	China	20-YEAR SURVIVAL DATA ANALYSIS OF PTCL PATIENTS IN PEKING UNIVERSITY CANCER HOSPITAL	Oral Presentation
112	O'Connor, Owen A.	United States	DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PERIPHERAL T-CELL LYMPHOMA: LEVERAGING A LOGIC FOR PD1/PDL-1 INHIBITORS	Oral Presentation
113	Huang, Huiqiang	China	Clinical Outcome of an Prospective, Multicentre, Randomized, Phase III Non-inferiority Clinical Trial for patients with extranodal NK/T cell lymphoma treated by P-Gemox or	Oral Presentation
114	de Leval, Laurence	Switzerland	NEW DATA IN THE MOLECULAR PATHOLOGY OF T-CELL LYMPHOMAS	Oral Presentation
115	Zhao, Weili	China	Diffuse Large B-cell Lymphoma: Using Immune Biomarkers to Define Novel Therapies	Oral Presentation
116	Federico, Massimo	Italy	THE T CELL PROJECT 2.0: THE MORE WE REGISTER, THE MORE WE LEARN.	Oral Presentation
117	Kwak, Larry	United States	Novel BAFF-R CAR T-cell Therapy for CD19 Antigen-loss Relapsed B Cell Tumors	Oral Presentation
118	Batlevi, Connie	United States	Phase I Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL including Richter transformation	Oral Presentation

119	Ramos, Carlos	United States	CD30-Chimeric Antigen Receptor (CAR) T cells for therapy of Hodgkin Lymphoma (HL)	Oral Presentation
120	Gauthier, Jordan	United States	Durable responses after CD19-targeted CAR-T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure	Oral Presentation
121	Hirayama, Alexandre	United States	High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T cell Immunotherapy	Oral Presentation
122	Siddiqi, Tanya	United States	Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-cell Non Hodgkin Lymphoma: First Results from the PLATFORM Study	Oral Presentation
123	Rajkumar, S. Vincent	United States	The High Cost of Cancer Drugs: What can we do?	Oral Presentation
124	Salles, Gilles	France	PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND)	Oral Presentation
125	Dickinson, Michael	Australia	BET inhibitor RG6146, venetoclax, and rituximab is a highly active regimen in relapsed/refractory (R/R) DLBCL: Initial report of phase 1b safety, biomarker, and response data	Oral Presentation
126	McMillan, Andrew	United Kingdom	Polatuzumab vedotin (Pola) + obinutuzumab (G) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Phase Ib/II interim analysis	Oral Presentation
127	Zelenetz, Andrew	United States	The PI3K δ Inhibitor ME-401 \pm Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), and Small Lymphocytic Lymphoma (SLL)	Oral Presentation
128	Ansell, Stephen	United States	Investigating safety and preliminary efficacy of AFM13 plus Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure	Oral Presentation
129	Falchi, Lorenzo	United States	Targeting the Peripheral T-Cell Lymphoma (PTCL) Epigenome with Oral 5-Azacytidine and Romidepsin: Results and Clinical-Molecular Correlations from a Phase 2 Study	Oral Presentation
130	Conconi, Annarita	Italy	Early progression of disease (POD24) predicts shorter survival in MALT lymphoma patients receiving systemic treatment.	Oral Presentation
131	Dr Ferreri, Andrés	Italy	INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE "IRIS" TRIAL	Oral Presentation
132	Bruscaggin, Alessio	Switzerland	Multi-omics landscape of Splenic Marginal Zone Lymphoma (SMZL) - Interim Analysis of IELSG46 study	Oral Presentation

133	Zinzani, Pier Luigi	Italy	Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open-label, registration directed phase 2 study	Oral Presentation
134	Castillo, Jorge	United States	Ibrutinib for the treatment of Bing-Neel syndrome: a retrospective, multicenter study	Oral Presentation
135	Treon, Steven	United States	Ibrutinib monotherapy produces long-term disease control in previously treated Waldenstrom's Macroglobulinemia: Final Report of the Pivotal Trial (NCT01614821).	Oral Presentation
136	Bommier, Côme	France	One-year real-life targeted next generation sequencing for lymphoma diagnosis: study of patients from the French Lymphoma Network in Rhône-Alpes	Poster Presentation
137	Rivas-Delgado, Alfredo	Spain	MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS	Poster Presentation
138	Camus, Vincent	France	Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study	Poster Presentation
139	Bobillo, Sabela	Spain	Analysis of Circulating Tumor DNA (ctDNA) in Cerebrospinal Fluid Detects the Presence of Central Nervous System (CNS) Involvement in B-Cell Lymphomas	Poster Presentation
140	Rymkiewicz, Grzegorz	Poland	Molecular analyses and an innovative diagnostic algorithm in MYC -negative Burkitt-like lymphoma with 11q aberration: a single institution experience	Poster Presentation
141	Husby, Simon	Denmark	High risk of adverse events after autologous stem-cell transplantation in lymphoma patients with DNA repair pathway mutations: A nation-wide cohort study	Poster Presentation
142	Okosun, Jessica	United Kingdom	EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS	Poster Presentation
143	Bolen, Christopher	United States	Treatment-dependence of high-risk gene expression signatures in <i>de novo</i> follicular lymphoma	Poster Presentation
144	Schmitt, Clemens	Austria	Personalized prediction in DLBCL enabled by functional mouse genomics	Poster Presentation
145	Thurner, Lorenz	Germany	SAMD14/Neurabin-I as BCR-antigens of Primary Central Nervous System Lymphoma	Poster Presentation
146	Patmore, Russell	United Kingdom	Population-Based Outcomes in Large B-cell lymphoma by WHO Subtype: Findings from the UK's Haematological Malignancy Research Network	Poster Presentation
147	Bossard, Celine	France	Refinement of MUM1 expression threshold for Double Positive CD10+ MUM1+ Diffuse Large B Cell Lymphoma allows a better Cell of Origin Classification for GCB subtype	Poster Presentation
148	Maguire, Alanna	United States	Reduced <i>BCL2</i> expression suggests alternative survival mechanisms in HIV(+) Diffuse Large B Cell Lymphoma (DLBCL) of Germinal Center Origin	Poster Presentation

149	Poon, Limei	Singapore	Single cell level analysis of MYC/ BCL2/ BCL6 co-expression in Diffuse large B-cell lymphoma through multiplexed quantitative immunofluorescence	Poster Presentation
150	Leppä, Sirpa	Finland	Clinical significance of T-cell exhaustion in patients with diffuse large B-cell lymphoma	Poster Presentation
151	Saito, Hideaki	Japan	The influence of tumor immune microenvironment and tumor immunity on the pathogenesis, treatment and prognosis of post-transplant lymphoproliferative disorders	Poster Presentation
152	Laurent, Camille	France	JAK-STAT pathway and epigenetic regulators are critical players in BI-ALCL pathogenesis ?	Poster Presentation
153	Ylstra, Bauke	Netherlands	Specific genetic alterations characterize Seroma- and Tumor-type Breast-implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) as a distinct disease entity	Poster Presentation
154	Huang, Dachuan	Singapore	Whole Genome Sequencing Reveals Potential Therapeutic Strategy for MEITL	Poster Presentation
155	Lim, Jing Quan	Singapore	Whole-genome sequencing reveals immunotherapeutic options for Natural-killer/T cell lymphoma patients.	Poster Presentation
156	Gualberto, Antonio	United States	KIR3DL2 Mutation may Define a High Rate of Response of AITL to Tipifarnib	Poster Presentation
157	Cheminant, Morgane	France	KIR3DL2 is expressed in peripheral T-cell lymphomas and may be a therapeutic target	Poster Presentation
158	Rodriguez, Marta	Spain	A PTCL gene signature capturing stromal and neoplastic data stratifies PTCL/NOS and AITL into different groups with variable survival probability	Poster Presentation
159	Baseggio, Lucile	France	Multicentric MFI30 study: standardization of CD30 expression by flow cytometry in Non-Hodgkin lymphoma.	Poster Presentation
160	van der Straten , Lina	Netherlands	Survival continues to increase in chronic lymphocytic leukemia: a population-based analysis among 20,324 patients diagnosed in the Netherlands between 1989 and 2015	Poster Presentation
161	van der Straten, Lina	Netherlands	Proteomics markers prognostic for outcome of chronic lymphocytic leukemia patients under treatment: results from the HOVON-109 study	Poster Presentation
162	Woyach, Jennifer	United States	Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up	Poster Presentation
163	Greil, Richard	Austria	Ibrutinib decreases obinutuzumab-induced secretion of cytokines associated with infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study	Poster Presentation
164	Sarraf Yazdy, Maryam	United States	Hypertension (HTN) in Patients (Pts) treated with Ibrutinib (Ibr) for Chronic Lymphocytic Leukemia (CLL)	Poster Presentation
165	Flinn, Ian	United States	An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 or more prior therapies	Poster Presentation
166	Ghia, Paolo	Italy	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory CLL/SLL in the DUO trial	Poster Presentation

167	Barrientos, Jacqueline	United States	Patterns of duvelisib-induced lymphocytosis in patients with R/R CLL or SLL including those with high-risk factors treated in the DUO trial	Poster Presentation
168	Pettitt, Andrew	United Kingdom	Brief co-administration of idelalisib may improve the long-term efficacy of frontline chemoimmunotherapy in chronic lymphocytic leukaemia: 3-year follow-up from the RIAItO trial	Poster Presentation
169	Egle, Alexander	Austria	Unmaintained Remission after Discontinuation of Kinase Inhibitor Treatment in Chronic Lymphocytic Leukemia: an Observational Cohort	Poster Presentation
170	Hoskin, Peter	United Kingdom	Long term follow up of FoRT: A Phase 3 Multi-Center Prospective Randomized Trial of Radiation Therapy for Follicular and Marginal Zone Lymphoma	Poster Presentation
171	MacManus, Michael	Australia	Systemic therapy after Radiation Therapy in stage I-II follicular lymphoma: Final results of an International Randomized Trial TROG 99.03	Poster Presentation
172	MacManus, Michael	Australia	Results of a Multicenter Phase2 Trial of Involved Field Radiotherapy Alone for Localized Non-Gastric Marginal Zone Lymphoma: TROG 05.02	Poster Presentation
173	Chau, Karen	United States	Outcomes of 180 Patients with Indolent Lymphomas Treated with Very Low Dose (4 Gy) Radiation Therapy Alone	Poster Presentation
174	Kalpadakis, Christina	Greece	CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): DESCRIPTION OF MAIN CLINICAL FEATURES, DISEASE EVOLUTION AND OUTCOME IN A SERIES OF 100 PATIENTS.	Poster Presentation
175	Ferrero, Simone	Italy	FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY	Poster Presentation
176	Olszewski, Adam	United States	Rituximab alone (R) versus rituximab plus bendamustine (BR) for splenic (SMZL) and nodal marginal zone lymphoma (NMZL).	Poster Presentation
177	Thieblemont, Catherine	France	Post hoc analyses of patients with relapsed/refractory marginal zone lymphoma who received lenalidomide plus rituximab (R ²) vs rituximab/placebo (AUGMENT)	Poster Presentation
178	Gribben, John	United Kingdom	AUGMENT: Relapsed/refractory indolent NHL patients were more sensitive to next treatment following lenalidomide/rituximab (R ²) than rituximab/placebo	Poster Presentation
179	Rule, Simon	United Kingdom	Efficacy and safety of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent NHL: results of the Phase III MabCute study	Poster Presentation
180	Maurer, Matthew	United States	Outcomes after early transformation (tPOD24) vs. early follicular lymphoma progression (fPOD24) in follicular lymphoma treated with frontline immunochemotherapy	Poster Presentation
181	Leonard, John	United States	Health-related quality of life (HRQoL) in relapsed/refractory (R/R) indolent NHL in the phase 3 AUGMENT trial of rituximab (R) plus lenalidomide (R ²) versus R plus placebo	Poster Presentation

182	Tohidi-Esfahani, Ibrahim	Australia	WhiMSICAL (Waldenström's Macroglobulinemia Study Involving CArt-wheel): A Global Patient-derived Data Registry Mapping Treatment and Quality of Life.	Poster Presentation
183	Tedeschi, Alessandra	Italy	Patient-reported outcomes (PROs) in Waldenström macroglobulinemia (WM) patients treated with ibrutinib-rituximab in the iNNOVATE study	Poster Presentation
184	Baldacini, Mathieu	France	Clinico-biological characteristics and treatment outcomes for Aggressive Mantle Cell Lymphoma patients included in clinical trials. A LYSA study.	Poster Presentation
185	Jain, Preetesh	United States	Comprehensive analysis of prognostic factors, outcomes and mutation profile in patients with aggressive histology (blastoid/pleomorphic) or transformed mantle cell lymphoma	Poster Presentation
186	Husby, Simon	Denmark	Evolution of clonal hematopoiesis in mantle cell lymphoma patients before, during, and after induction chemotherapy and autologous stem cell transplantation	Poster Presentation
187	Sharman, Jeff	United States	MAGNIFY phase IIIb interim analysis: First report of induction R ² followed by maintenance in patients with relapsed/refractory mantle cell lymphoma	Poster Presentation
188	Eskelund, Christian	Denmark	Early progression of mantle cell lymphoma depicts a high-risk disease with poor response to subsequent therapies and a dismal outcome	Poster Presentation
189	Burney, Claire	United Kingdom	The efficacy of ibrutinib in patients with relapsed mantle cell lymphoma after first line intensive chemo-immunotherapy and ASCT – a retrospective study from the LWP-EBMT	Poster Presentation
190	Rusconi, Chiara	Italy	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA	Poster Presentation
191	Tam, Constantine	Australia	Updated Safety and Efficacy Data in the Phase 1 Trial of Patients with Mantle Cell Lymphoma (MCL) Treated with Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib (BGB-3111)	Poster Presentation
192	Flowers, Christopher	United States	The Clinical Course of Diffuse Large B-cell Lymphoma (DLBCL) over Time: A Multistate Survival Analysis Using Meta-Data From 13 First-line Randomized Trials	Poster Presentation
193	Schmitz, Norbert	Germany	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): an individual patient-level analysis across international trial	Poster Presentation
194	Spina, Michele	Italy	The Elderly Project by the Fondazione Italiana Linfomi: a Prospective Comprehensive Geriatric Assessment (CGA) of 1353 Elderly Patients with Diffuse Large B-Cell Lymphoma.	Poster Presentation
195	Berry, Donald	United States	PET-CR as a Surrogate for Survival Outcomes in DLBCL: A Literature Based Meta-Analysis	Poster Presentation
196	Bobillo, Sabela	United States	Clinical Characteristics and Outcomes of Stage I Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab-Era	Poster Presentation
197	Issa, Djamila	Netherlands	Population-based study on different regimens of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma in the Netherlands supports the use of 6 cycles of R-CHOP21	Poster Presentation

198	Balzarotti, Monica	Italy	PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL)	Poster Presentation
199	Verner, Emma	Australia	SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL	Poster Presentation
200	Lammer, Felicitas	Germany	Prospective multicenter registry for secondary CNS involvement in malignant lymphoma: an update with data from 181 patients	Poster Presentation
201	Ferreri, Andrés	Italy	LONG-TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT)	Poster Presentation
202	Sehn, Laurie	Canada	Estimation of long-term survival with polatuzumab vedotin plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)	Poster Presentation
203	de la Cruz-Merino, Luis	Spain	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Preliminary results of the R2-GDP-GOTEL Trial	Poster Presentation
204	Imber, Brandon	United States	MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before CD19 CAR T Therapy	Poster Presentation
205	Yang, Joanna	United States	Highly Favorable Outcomes with RT Followed by ASCT in Low/Low-Intermediate Secondary Age Adjusted IPI Rel/Ref DLBCL Patients Refractory to Salvage Chemotherapy	Poster Presentation
206	Fujimoto, Ayumi	Japan	Post-transplant Lymphoproliferative Disorder in Patients with Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation	Poster Presentation
207	Raderer, Markus	Austria	Depth of remission following first line HP-eradication is an independent prognostic factor in gastric MALT lymphoma	Poster Presentation
208	Marangon, Miriam	Italy	⁹⁰ Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) – The Zeno Study	Poster Presentation
209	Kiesewetter, Barbara	Austria	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including PCR-based clonality analysis	Poster Presentation
210	Rajeeve, Sridevi	United States	Incidence and Treatment Outcomes of Patients with Transformed Marginal Zone Lymphoma Treated with RCHOP-Like Regimens	Poster Presentation
211	Kondo, Eisei	Japan	Allogeneic hematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: Data from the Japan Society for Hematopoietic Cell Transplantation (JSHCT) registry	Poster Presentation

212	Vassilakopoulos, Theodoros	Greece	PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT)	Poster Presentation
213	Trneny, Marek	Czech Republic	Is it radiotherapy necessary for primary mediastinal B-cell lymphoma (PMBL) patients achieving PET negativity after immunochemotherapy?	Poster Presentation
214	Mei, Qian	China	PD-1 Inhibitor plus Chemotherapy in Relapsed/refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL) with Aggressive Bulky Disease	Poster Presentation
215	Choquet, Sylvain	France	Temozolomide in relapse/refractory primary vitreo-retinal lymphoma (R/R PVRL): a simple, cheap, effective and well tolerated treatment. Result of the largest study on R/R PVRL, from the LOC network	Poster Presentation
216	Novo, Mattia	United States	Clinical features, treatment and outcome of Neurolymphomatosis: Single Institution experience	Poster Presentation
217	Schorb, Elisabeth	Germany	Bicentric pilot study on age-adapted high-dose chemotherapy and autologous stem cell transplant in newly diagnosed primary CNS lymphoma patients > 65 years - MARiTA trial	Poster Presentation
218	Cheminant, Morgane	France	Membrane Expression of NK Receptor KIR3DL2 Contributes to Delineate the Acute-type and is a Therapeutic Target in Adult T-cell Leukemia/lymphoma	Poster Presentation
219	Couronné, Lucile	France	PD-1 blockade in a French series of 13 relapsed / refractory NK/T-cell lymphoma patients	Poster Presentation
220	Hu, Shaoxuan	China	A prospective phase II study of pegaspargase-COEP plus radiotherapy in patients with newly diagnosed extra-nodal NK/T-cell lymphoma	Poster Presentation
221	Lin, Tongyu	China	A prospective study of MRI and PET/CT-guided therapy for improving survival in upper aerodigestive tract Natural Killer/T-cell lymphoma, nasal type	Poster Presentation
222	Yamaguchi, Motoko	Japan	CLINICAL OUTCOMES AND DIAGNOSIS-TO-TREATMENT INTERVAL IN PATIENTS WITH NK/T-CELL LYMPHOMA: 7-YEAR FOLLOW-UP OF THE NKEA STUDY	Poster Presentation
223	Suzuki, Takaharu	Japan	Clinicopathological differences of nodal PTCL with Tfh phenotype from AITL and PTCL, NOS, and detection of prognostic marker of nodal PTCL with Tfh phenotype	Poster Presentation
224	Wudhikarn, Kitsada	Thailand	EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP	Poster Presentation
225	Lemonnier, François	France	Bone Marrow Involvement, but No Blood Involvement, Impairs Survival in Angioimmunoblastic T cell Lymphoma: An Ancillary Study of the REVAIL Trial	Poster Presentation
226	Zhou, Daobin	China	Combination of chidamide with CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: A prospective, multicenter, single-arm, phase 1b/2 trial	Poster Presentation

227	Lunning, Matthew	United States	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results	Poster Presentation
228	Illidge, Tim	United Kingdom	Response to A+CHP by CD30 expression in the ECHELON-2 trial	Poster Presentation
229	Shustov, Andrei	United States	Anaplastic Large Cell Lymphoma, ALK-Negative: analysis of 235 Cases collected by the T-Cell Project.	Poster Presentation
230	Lazaryan, Aleksandr	United States	Increased Risk of Second Primary Hematologic and Solid Malignancies in Patients with Mycosis Fungoides: Impact on Overall Survival in SEER Registry	Poster Presentation
231	Kim, Youn	United States	Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: a post-hoc analysis of the MAVORIC study	Poster Presentation
232	Horwitz, Steven	United States	Final data from the phase 3 ALCANZA study: Brentuximab vedotin (BV) vs physician's choice (PC) in patients (pts) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL)	Poster Presentation
233	Zambello, Renato	Italy	CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS.	Poster Presentation
234	Aeppli, Stefanie	Switzerland	Clinical characteristics and outcome of patients with Hodgkin's lymphoma older than 60 years treated in Switzerland over the last 17 years	Poster Presentation
235	Radford, John	United Kingdom	Exploratory biomarker analysis in the Ph 3 ECHELON-1 study: Worse outcome with ABVD in patients with elevated baseline levels of sCD30 and TARC	Poster Presentation
236	Mazza, Rita	Italy	DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI	Poster Presentation
237	Gallamini, Andrea	France	Brentuximab-Vedotin and Bendamustine is a feasible and effective drug combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).	Poster Presentation
238	Herrera, Alex	United States	PET-adapted nivolumab +/- ICE as initial salvage therapy in relapsed/refractory Hodgkin lymphoma	Poster Presentation
239	Lim, Sean	United Kingdom	Transcriptional networks associated with treatment failure in advanced-stage Hodgkin lymphoma: data from the RATHL trial (CRUK/07/033)	Poster Presentation
240	Gac, Anne-Claire	France	Outcome and treatment of relapsing earlyPETnegative patients included in the EORTC/LYSA/FIL H10 trial on stages I/II Hodgkin lymphoma	Poster Presentation
241	Stefoni, Vittorio	Italy	First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of FIL ONLUS	Poster Presentation
242	Zinzani, Pier Luigi	Italy	Phase 1b KEYNOTE-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up	Poster Presentation

243	De Philippis, Chiara	Italy	CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES	Poster Presentation
244	Bazarbachi, Ali	Lebanon	How to select donor, stem cell source, and conditioning regimen for haploidentical transplants with post-transplant cyclophosphamide for lymphoma: a report of the EBMT	Poster Presentation
245	Castagna, Luca	Italy	Impact of Class II HLA mismatch on clinical outcomes in Hodgkin lymphoma patients receiving haploidentical stem cell transplantation (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy).	Poster Presentation
246	Thieblemont, Catherine	France	REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM	Poster Presentation
247	Wang, Michael	United States	Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001	Poster Presentation
248	Neelapu, Sattva	United States	Outcomes of patients ≥ 65 years of age in ZUMA-1, a pivotal Phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma	Poster Presentation
249	Sano, Dahlia	United States	Safety and Efficacy of Axicabtagene Ciloleucel (axi-cel) in Older Patients: Results from The US Lymphoma CAR-T Consortium	Poster Presentation
250	Topp, Max	Germany	Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B cell lymphoma	Poster Presentation
251	Caimi, Paolo	United States	Phase 1 Study of AntiCD19 CAR-T Cells with TNF α Transmembrane Domain and 41BB, CD3 ζ Costimulatory Domains. Responses in Subjects with Rapidly Progressive Lymphoma	Poster Presentation
252	Wang, Yao	China	CD19/CD20-redirected bispecific CAR T cell treatment in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma	Poster Presentation
253	Maziarz, Richard	United States	Cytokine Release Syndrome and Neurotoxicity by Baseline Tumor Burden in Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Tisagenlecleucel	Poster Presentation
254	Bachanova, Veronika	United States	Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients	Poster Presentation
255	Sehn, Laurie	Canada	Managing cytokine release syndrome (CRS) and neurotoxicity with step-up dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL)	Poster Presentation
256	Strati, Paolo	United States	Clinical Implications of Cytopenias Beyond Day 30 after Axi-cel Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma	Poster Presentation

257	Anand, Kartik	United States	Comprehensive report of anti-CD19 chimeric antigen receptor T-cells (CAR-T) associated Non Relapse Mortality (CART-NRM) from FAERS	Poster Presentation
258	Shadman, Mazyar	United States	Safety of Allogeneic Hematopoietic Cell Transplant in Adults after CD19 Targeted Chimeric Antigen Receptor-modified T-cell (CAR-T) Therapy	Poster Presentation
259	Sawas, Ahmed	United States	Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)	Poster Presentation
260	Khoury, Issa	United States	Ipilimumab plus Lenalidomide for Treatment of Relapsed Disease after Allogeneic Stem Cell Transplantation (AlloSCT) in Patients (pts) with Lymphoid Malignancies	Poster Presentation
261	Robinson, Stephen	France	Donor lymphocyte infusions induce durable responses in patients with follicular, mantle and T cell lymphomas relapsing after an alloSCT. An EBMT-LWP Study.	Poster Presentation
262	Cox, Christina	United Kingdom	INTRANODAL TREATMENT WITH IFNA-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY	Poster Presentation
263	Tarantelli, Chiara	Switzerland	Copanlisib synergies with conventional and targeted agents including venetoclax in preclinical models of B- and T-cell lymphomas	Poster Presentation
264	Arribas, Alberto	Switzerland	Mechanisms of secondary resistance to Idelalisib in marginal zone lymphoma	Poster Presentation
265	Buggy, Joseph	United States	A Selective and Covalent Inhibitor of ITK Blocks TCR Signaling, Inhibits Proliferation of Human Sézary Cells In Vitro, and Induces Tumor Regression in Dogs with T-cell Lymphoma	Poster Presentation
266	Seymour, Erlene	United States	Nuclear Export Inhibition enhances the activity of R-CHOP in Non-Hodgkin's Lymphoma	Poster Presentation
267	Jiménez, Isabel	Spain	Reversal of immune tolerance and increased survival after XPO1 and BTK inhibition in mouse models of primary CNS lymphoma (PCNSL)	Poster Presentation
268	Spriano, Filippo	Switzerland	The first-in-class ETS inhibitor TK-216 interferes with ETS transcription factors and synergize with lenalidomide in lymphoma	Poster Presentation
269	Normant, Emmanuel	United States	The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHL	Poster Presentation
270	Spriano, Filippo	Switzerland	The anti-CD25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines	Poster Presentation
271	Molina, Arturo	United States	Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in advanced B-cell malignancies.	Poster Presentation
272	Dufner, Vera	Germany	Long-term outcome of patients with relapsed/refractory B-cell non- Hodgkin lymphoma treated with bispecific antibody blinatumomab in a phase I trial	Poster Presentation

273	Pinto, Antonello	Italy	A first-in-human trial of the novel multi-action therapy tinostamustine (EDO-S101) in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL)	Poster Presentation
274	Belada, David	Czech Republic	Phase 2 Study of Parsaclisib (INCB050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (CITADEL-202)	Poster Presentation
275	Witzig, Thomas	United States	Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Phase 1/2 Study	Poster Presentation
276	Gregory, Gareth	Australia	ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY	Poster Presentation
277	Caimi, Paolo	United States	Safety and efficacy of venetoclax combined with rituximab, ifosfamide, carboplatin and etoposide (VICER) for treatment of relapsed DLBCL: Final results from the Phase 1 Trial	Poster Presentation
278	Michot, Jean-Marie	France	Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Poster Presentation
279	Sermer, David	United States	Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) and follicular lymphoma (FL)	Poster Presentation
280	Herbaux, Charles	France	Safety and efficacy of atezolizumab, obinutuzumab and venetoclax combination for relapsed/refractory non-Hodgkin lymphomas: Results from the safety-run of a LYSA study	Poster Presentation
281	Melani, Christopher	United States	Phase 1B Study of ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis	Poster Presentation
282	Wang, Michael	United States	Results From the Safety Run-In Period of the SYMPATICO Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma	Poster Presentation
283	Ai, Wei	United States	Phase I study of romidepsin and liposomal doxorubicin in relapsed or refractory T-cell lymphoma	Poster Presentation
284	Porcu, Pierluigi	United States	A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLOVIR (VG) IN SUBJECTS WITH EPSTEIN-BARR VIRUS (EBV)-ASSOCIATED LYMPHOMAS	Poster Presentation
285	Kotchetkov, Rouslan	Canada	Improvement of Rituximab administration by premedication with rupatadine, montelukast and their combination	Poster Presentation
286	Song, Hyojin	Korea, Republic of	Multi-omics approaches to understand gastric Mucosa-Associated Lymphoid Tissue (MALT) lymphoma	Publication
287	Paydas, Semra	Turkey	The role of DUSP22 (Dual Specificity Phosphatase 22) gene expression in the prognosis of low grade lymphomas	Publication
288	Miyazaki, Kana	Japan	Gene mutations and sites of involvement in duodenal-type follicular lymphoma	Publication

289	Salazar-Vargas, Ana	Mexico	PREVALENCE OF EPSTEIN BARR VIRUS IN FOLLICULAR LYMPHOMA AND PROGNOSTIC VALUE OF FOXP1 AND P53 BIOMARKERS IN A MEXICAN POPULATION	Publication
290	Le Bris, Yannick	France	Increased <i>CCND1</i> FISH signals are associated with worse prognosis in mantle cell lymphoma.	Publication
291	Wang, Yu-Hung	Taiwan (Republic of China)	Quantifying somatic hypermutation rates and identifying immunoglobulin heavy chain stereotypes in mantle cell lymphoma through next-generation sequencing	Publication
292	Rodrigues, Joana	Sweden	The immune microenvironment as a prognostic tool for MCL patients	Publication
293	Sasaki, Nobuyoshi	Japan	Mutation of <i>PIM1</i> gene in Primary Central Nervous System Lymphoma inhibits cell death through change in subcellular localization of Pim-1 and increase of BAD phosphorylation.	Publication
294	de Jong, Daphne	Netherlands	Clinically indolent primary HHV8-negative effusion-based lymphoma is characterized by complex genomic alterations with aggressive features	Publication
295	Rivas-Delgado, Alfredo	Spain	GENOTYPING PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS	Publication
296	Halytskiy, Volodymyr	Ukraine	Abnormalities in microRNA expression signature can contribute to the genome instability and failure of DNA repair mechanisms in case of diffuse large B-cell lymphoma	Publication
297	El-Sharkawi, Dima	United Kingdom	Comparison of outcomes between patients with <i>MYC</i> rearranged DLBCL and double/triple hit high-grade B cell lymphoma: a Pan-London retrospective review.	Publication
298	Sermer, David	United States	Clinical significance and outcomes in patients with diffuse large B-cell lymphoma (DLBCL) harboring extra copies [EC] and/or translocations [TL] of <i>MYC</i> , <i>BCL2</i> , and <i>BCL6</i> .	Publication
299	Roulin, Louise	France	Clinical, immunophenotypic and genetic characteristics of aggressive (non-Burkitt) B-cell lymphoma in a real life cohort	Publication
300	Downer, Mary	United States	Real-world prognostic impact of <i>BCL2</i> and <i>MYC</i> expression and translocation among diffuse large B-cell lymphoma patients treated with first-line R-CHOP	Publication
301	Rodriguez, Marta	Spain	Diffuse large B-cell lymphoma survival prognostication, a comparative analysis of Cell of Origin vs. <i>MYC/BCL2</i> expression	Publication
302	Su, Yung-Cheng	Taiwan (Republic of China)	A New Proposal for Identification of Double-Hit Diffuse Large B-Cell Lymphoma Based on the Predominance of Double Hits Involving <i>BCL6</i> Rearrangement in Taiwan	Publication
303	Favre, Simon	France	Outcome of patients with c-myc rearranged diffuse large B cell lymphoma associated or not with <i>Bcl2</i> and/or <i>Bcl6</i> rearrangement : a multicentric and retrospective study.	Publication
304	Jeyasekharan, Anand	Singapore	Digital spatial profiling of immune markers in R-CHOP treated diffuse large b-cell lymphoma reveals a dominant prognostic significance of M2 macrophage infiltration	Publication

305	Wang, Xianhuo	China	A2aR as one of novel immune checkpoints, and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma	Publication
306	Cervera, Pascale	France	Morphological evaluation of the immune profile in a series of diffuse large B cells lymphoma in tissue microarrays : preliminary results.	Publication
307	Li, Xiao-Qiu	China	Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression	Publication
308	Li, Xiao-Qiu	China	Latent membrane protein 2A (LMP2A) mimics B-cell receptor signaling and promotes immune escape in Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL)	Publication
309	Cencini, Emanuele	Italy	Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in newly diagnosed diffuse large B-cell lymphoma patients	Publication
310	Samarina, Svetlana	Russian Federation	The significance of PD-L1 and PD1 receptors expression in patients with diffuse B-cell large-cell lymphoma	Publication
311	Bloehdorn, Johannes	Germany	Clinical presentation and molecular characteristics of cutaneous DLBCL	Publication
312	Baile, Mónica	Spain	EVALUATION OF BONE MARROW INFILTRATION BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: SUB-STUDY OF A PHASE 2 GELTAMO CLINICAL TRIAL	Publication
313	Jin, Fengyan	China	Activation of the AhR/ARNT pathway is associated with outcome of DLBCL patients after treated with rituximab	Publication
314	Poirel, H�el�ene	Belgium	Genetic predisposition of familial Hodgkin lymphoma	Publication
315	Das, Mayurakshi	India	'Not so Classical': A Study of the Immunoprofile in Classical Hodgkin Lymphoma, an experience from a Referral Center	Publication
316	Kuhnert, Frank	United States	Pre-T cell receptor signaling drives leukemogenesis and is a therapeutic target in T cell acute lymphoblastic leukemia	Publication
317	Sayinalp, Nilgun	Turkey	THE EVALUATION OF THE CLINICOPATHOLOGIC CHARACTERISTICS OF T-CELL NON-HODGKIN'S LYMPHOMA: THE SINGLE CENTER EXPERIENCE	Publication
318	Yang, Haiyan	China	Potential Metabolites with diagnostic value in Plasma for Angioimmunoblastic T-cell lymphoma by LC-MS Based Untargeted Metabonomics Study	Publication
319	Wang, Xianhuo	China	Prognostic significance of PD-L1 and phosphorylated ERK expression in T-cell lymphoma: PD-1/PD-L1 axis activates intracellular ERK signaling in tumor cells	Publication
320	Takeuchi, Mai	Japan	Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T-cell leukemia/lymphoma	Publication

321	Xu, Jingyan	China	Safety and efficacy of ultrasound-guided coarse needle biopsy in the diagnosis of suspected lymphoma	Publication
322	Gonzalez-Rodriguez, Ana Pilar	Spain	Image-Guided Core Biopsy is safe and effective for the diagnosis of lymphoma	Publication
323	Le Bris, Yannick	France	Validation of real-time multiplex ligation probe amplification (RT-MLPA) to analyze lymphoma transcriptome from formalin-fixed paraffin embedded samples.	Publication
324	Mollaret, Emeline	France	CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD	Publication
325	Adila, Nur	Malaysia	EPIDEMIOLOGY REVIEW OF LYMPHOMA IN A SINGLE INSTITUTION IN MALAYSIA	Publication
326	Jiménez Galainena,	Cuba	Histopathological and immunohistochemical study of malignant lymphomas.	Publication
327	Zhu, Huayuan	China	PTBP1 regulates alternative splicing of apoptotic protein:Implications in CLL and Ibrutinib resistance	Publication
328	Xu, Wei	China	EBV-miR-BHRF1-1 targets p53 gene: potential role in Epstein-Barr virus associated chronic lymphocytic leukemia	Publication
329	Papageorgiou, Sotirios	Greece	The tRNA-derived RNA fragments (tRFs) bearing the Glycine anticodons GCC and CCC as emerging molecular biomarkers of unfavorable prognosis in chronic lymphocytic leukemia	Publication
330	Mardaraz, Claudia	Argentina	Results of Mutational Status of Immunoglobulin heavy-chain variable genes analysis in a cohort of patients with B-CLL. A single centre experience.	Publication
331	Kogarko, Iveta	Russian Federation	Changes in concentration of serum free light chains of immunoglobulins in patients with chronic lymphocytic leukemia as a factor for evaluating chemotherapy effectiveness	Publication
332	De Silva, Pushpamali	Belgium	FOXP1, PD-1 and PD-L1 ARE SIGNIFICANTLY UPREGULATED IN LYMPHOCYTES FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGE-MATCHED HEALTHY DONORS	Publication
333	Zou, Yi-Xin	China	The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	Publication
334	Hughes, Mitchell	United States	Real world outcomes of obinutuzumab monotherapy in patients with chronic lymphocytic leukemia	Publication
335	Santamaria Lopez, Ana	Spain	Role of chlorambucil in combination or not with anti-CD20 as frontline therapy in chronic lymphocytic leukemia in "real life"	Publication

336	García-Marco, José Antonio	Spain	A phase II trial to evaluate the efficacy and safety of the combination of obinutuzumab bendamustine treatment in patients with relapsed /refractory chronic lymphocytic leukemia	Publication
337	Bond, David	United States	Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors	Publication
338	Gendlin, Gennady	Russian Federation	ANTICOAGULANT THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING IBRUTINIB.	Publication
339	Calleja, Anne	France	Ibrutinib above 79 years old for chronic lymphocytic leukemia: important toxicities	Publication
340	Willis, Lauren	United States	Using BTK Inhibitors for Chronic Lymphocytic Leukemia: Online Education Significantly Improved the Knowledge and Competence of Hematologists/Oncologists	Publication
341	Brown, Jennifer	United States	Idelalisib plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL	Publication
342	Launonen, Aino	Switzerland	Clinical outcomes of patients with intermediate-to-high-risk follicular lymphoma (FL) in the GALLIUM phase III study	Publication
343	Dreyling, Martin	Germany	Efficacy and safety in high-risk relapsed or refractory indolent follicular lymphoma patients treated with copanlisib	Publication
344	Zinzani, Pier Luigi	Italy	Safety analysis of patients with a medical history of respiratory disorders treated with copanlisib from the CHRONOS-1 study in relapsed or refractory indolent B-cell lymphoma	Publication
345	Poh, Christina	United States	A Phase II Trial of Rituximab/Lenalidomide followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow up and Correlative Analysis	Publication
348	Imber, Brandon	United States	Grade 3A Follicular Lymphoma Can Be Effectively Controlled with Very Low Dose Radiation Therapy	Publication
349	Kanno, Masatoshi	Japan	Consolidation therapy using ⁹⁰ Y-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma; a multicenter, phase II study (BRiZ2012)	Publication
350	Guerra, Luca	Italy	Interim analysis of Central Review of End-of-Therapy PET in FOLL12 Trial for Follicular Lymphoma	Publication
351	Yuasa, Mitsuhiro	Japan	Clinical significance of uptake value on F18-FDG PET/CT and histological grade in 164 patients with follicular lymphoma including transformation – A single Center Retrospective Study	Publication
352	Durot, Eric	France	Follicular lymphoma : pre-treatment TEP/CT scan texture parameters as predictive biomarkers of progression free survival and time to next treatment	Publication
353	Hatta, Shunsuke	Japan	The role of surveillance computed tomography in patients with follicular lymphoma	Publication

354	Mozas, Pablo	Spain	PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE	Publication
355	Liu, Jiajia	Canada	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy	Publication
356	Ďuraš, Juraj	Czech Republic	Predictive value of PRIMA-prognostic index (PRIMA-PI) in first relapse of follicular lymphoma	Publication
357	Panayiotidis,	Greece	Copanlisib treatment of patients with relapsed or refractory marginal zone lymphoma	Publication
358	Jacobsen, Eric	United States	Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial	Publication
359	Durot, Eric	France	A PROGNOSTIC SCORE FOR TRANSFORMED WALDENSTROM MACROGLOBULINEMIA	Publication
360	Lokhande, Lavanya	Sweden	Serum biomarkers are associated with treatment response in relapsed Mantle Cell Lymphoma	Publication
361	Xu, Wei	China	High viral loads of circulating Epstein-Barr virus DNA copy number in peripheral blood is associated with inferior prognosis in patients with mantle cell lymphoma	Publication
362	Hughes, Mitchell	United States	Obinutuzumab therapy in patients with marginal zone and mantle cell lymphoma	Publication
363	Hill, Brian	United States	Maintenance Rituximab is Associated with Improved Overall Survival in Mantle Cell Lymphoma Patients Responding to Induction Therapy with Bendamustine + Rituximab (BR)	Publication
364	Goker, Hakan	Turkey	MANTLE CELL LYMPHOMA: TWO REFERENCE CENTER'S RESULTS	Publication
365	Bond, David	United States	Outcomes for Patients with Mantle Cell Lymphoma Experiencing Frontline Treatment Failure: A Multicenter Retrospective Study	Publication
366	Willis, Lauren	United States	Online Education Significantly Improved the Competence of Hematologists/Oncologists and Nurses Regarding the Use of BTK Inhibitors for Mantle Cell Lymphoma	Publication
367	Westin, Jason	United States	Very Early FDG PET/CT Scan May Predict Outcomes in Relapsed or Refractory DLBCL Patients Treated with Salvage Therapy	Publication
368	Fiskvik, Idun	Norway	Prognostic value of baseline FDG PET parameters in high risk diffuse large B-cell lymphoma patients	Publication
369	Xu, Wei	China	C-reactive protein-to-albumin ratio is an independent poor prognosis and improving NCCN-IPI score in newly diagnosed diffuse large B-cell lymphoma: a clinical analysis of 414 cases	Publication
370	Zerga, Marta	Argentina	RELATIONSHIP BETWEEN SOCIOECONOMIC FACTORS AND DELAY IN DIAGNOSIS AND INITIAL TREATMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). DO THESE FACTORS IMPACT ON THE RESPONSE RATE?. RESULTS OF A MULTICENTRIC ARGENTINIAN STUDY	Publication

371	Janikova, Andrea	Czech Republic	PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE.	Publication
372	Casan, Joshua	Australia	Short diagnosis-to-treatment interval is associated with high risk and poor outcomes in diffuse large B-cell lymphoma	Publication
373	Liu, Peng	China	A retrospective analysis of real-world outcomes of Chinese elder patients with diffuse large B cell lymphoma (DLBCL)	Publication
374	Xu, Wei	China	Hypogammaglobulinemia and hypocomplementemia as strong prognostic factors in newly diagnosed diffuse large B cell lymphoma	Publication
375	Ilhan, Osman	Turkey	Age is not Important in Fit Elderly Patients with aggressive lymphoma	Publication
376	Clausen, Michael	Denmark	Pre-treatment hemoglobin and outcome in patients with diffuse large B-cell lymphoma treated with anthracycline containing chemotherapy	Publication
377	Bellesso, Marcelo	Brazil	Real life data about characteristics, standard treatment and outcomes in Brazilian elderly patients with Diffuse large B-cell Lymphoma – a single center analysis.	Publication
378	Abadi, Uri	Israel	Prevalence and Clinical Significance of Hypercalcemia at Diagnosis in Diffuse Large B Cell Lymphoma	Publication
379	Xu, Wei	China	The criteria of interim therapy change for patients with diffuse large B-cell lymphoma: interim Δ SPD less than 80% vs. 50%	Publication
380	Kurukulasuriya, Nuwan	United States	Treatment pathways of Diffuse Large B-cell Lymphoma in German claims data	Publication
381	Lee, Dong Soo	Korea, Republic of	Treatment Outcomes of Limited-Field Radiotherapy in Elderly Patients with High-grade or Recurrent Non-Hodgkin Lymphoma	Publication
382	Gupta, Sanjiv	Australia	Outcome after salvage radiotherapy to FDG-PET/CT avid disease post chemotherapy in advanced stage diffuse large B-cell lymphoma (DLBCL).	Publication
383	Pasvolsky, Oren	Israel	R-CHOP vs. R-CHOP+X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis	Publication
384	Vander Velde, Nancy	United States	A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)	Publication
385	Michalarea, Vasiliki	United Kingdom	Excellent outcomes using rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone (R-GCVP) in patients with DLBCL and cardiac comorbidities.	Publication

386	Yang, Shenmiao	China	First-line therapy of elderly patients with DLBCL-a comparison of study patients treated with R-CHOP on the RICOVER-60 trial and patients treated with R-Cyclophosphamide, Epirubicin, Vindesine, Prednisone (R-EpiVDSP) at Peking University.	Publication
387	Gini, Guido	Italy	Lenalidomide and Rituximab (ReRi) as front line therapy of elderly frail patients with Diffuse Large B-cells Lymphoma. First planned interim analysis of a phase II study of the Fondazione Italiana Linfomi (FIL)	Publication
388	Herrera, Alex	United States	Real-world bendamustine use in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)	Publication
389	Cazelles, Clarisse	France	Rituximab plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. A real life study in patients ineligible for autologous transplantation	Publication
390	Viardot, Andreas	Germany	Durability of Complete Response After Blinatumomab Therapy for Refractory/Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma	Publication
391	Uryu, Hideki	Japan	The rituximab maintenance therapy improves prognosis of transformed diffuse large B cell lymphoma	Publication
392	Frontzek, Fabian		Intensive immunochemotherapy (R-CHOEP) vs high-dose immunochemotherapy (R-MegaCHOEP) in young patients with aggressive B-cell lymphoma: a 10-year long-term follow-up	Publication
393	Panny, Michael	Austria	Treatment of high risk aggressive B cell lymphomas with DA EPOCH R– the austrian experience	Publication
394	Bouabdallah, Réda	France	A phase II study of Lenalidomide and Rituximab (R ²) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma	Publication
395	Šimkovič, Martin	Czech Republic	DA-EPOCH-R versus R-CHOP in high risk DLBCL patients: analysis of the Czech Lymphoma Study Group (CLSG)	Publication
396	Adila, Nur	Malaysia	UPFRONT AHST IN NON HODGKIN LYMPHOMA-BETTER OUTCOME?	Publication
397	Romejko-Jarosinska, Joanna	Poland	Outcome of patients with aggressive B-cell lymphoma who failed to proceed to or relapsed after high dose chemotherapy and autologous hematopoietic cell transplantation	Publication
398	Casan, Joshua	Australia	R-IVAC salvage therapy in relapsed and refractory DLBCL	Publication
399	Paszkiwicz-Kozik, Ewa	Poland	Ofatumumab with IVAC for DLBCL patients who failed R-CHOP and were not candidates for high-dose therapy and ASCT - phase 2 trial of the Polish Lymphoma Research Group (PLRG-8).	Publication
400	Tang, Catherine	Canada	Efficiency and safety of stem cell mobilization following GDP salvage in patients with relapsed or refractory lymphoma	Publication

401	Sauter, Craig	United States	Allogeneic Hematopoietic Cell Transplantation Impacts on Immune Evasive Mechanisms in Relapsed/Refractory Diffuse Large B-cell Lymphoma – A Single Center Experience	Publication
402	Lepkov, Sergey	Russian Federation	Antiviral therapy and immunochemotherapy in patients with diffuse B-cell large lymphoma (DLCL) with hepatitis C (HCV)	Publication
403	Huang, Haiwen	China	Haploidentical hematopoietic stem cell transplantation compared with HLA-matched stem cell transplantation for refractory or relapsed aggressive non-Hodgkin lymphoma	Publication
404	Brodie, Rachel	Ireland, Republic of	A national retrospective analysis of clinical outcomes following allogeneic transplantation for High Grade B-Cell Lymphoma (HGBL).	Publication
405	Farina, Giuliana	Italy	The addition at day 9 of HD-MTX to the (DA)-EPOCH scheme with or without Rituximab is an effective regimen in untreated advanced stage high risk lymphoma: a feasibility study.	Publication
406	Dabaja, Bouthaina	United States	DIFFUSE LARGE B CELL LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT: CAN MRI PATTERN HELP PREDICTING OUTCOME?	Publication
407	Wilson, Matthew	United Kingdom	Tolerability of high dose intravenous methotrexate for CNS prophylaxis intercalated with R-CHOP – a single centre retrospective analysis	Publication
408	Welslau, Manfred	Germany	Sandoz rituximab for treatment of diffuse large B-cell lymphoma: interim safety results of the non-interventional, observational, multicenter, open-label REFLECT study	Publication
409	Zinzani, Pier Luigi	Italy	REAL WORLD EFFECTIVENESS AND SAFETY OF CT-P10 IN DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY	Publication
410	Jeong, Seong Hyun	Korea, Republic of	A prospective registry study of Peg-G-CSF prophylaxis for patients with diffuse large B-cell lymphoma (CISL 1403)	Publication
411	Sun, Xuemei	China	Clinical Observation of Metronomic Chemotherapy Combined with Clearing Heat and Detoxicating Traditional Chinese Medicine in the Treatment of Refractory and Relapsed Elderly Lymphoma	Publication
412	Frikha, Imen	Tunisia	Outcome of children and adolescents with lymphoblastic lymphoma treated with the EORTC 58951 protocol	Publication
413	Kiesewetter, Barbara	Austria	First line systemic treatment in mucosa-associated lymphoid tissue (MALT) lymphoma not eligible for H. pylori eradication – do we need chemotherapy?	Publication
414	Romejko-Jarosinska, Joanna	Poland	Primary breast diffuse large B-cell lymphoma. Clinical features and outcome in 55 patients. Polish Lymphoma Research Group Study	Publication
415	Vinogradova, Julia	Russian Federation	IMMUNOCHEMORADIOTHERAPY OR IMMUNOCHEMOTHERAPY ONLY IN PATIENTS WITH EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMA OF STOMACH	Publication

416	Yuille, Frances	United Kingdom	Incidental Radiation to the Spleen After Treating Gastric Lymphoma with Radical Radiotherapy – Should We Recommend Prophylactic Immunisation and an OAR dose constraint?	Publication
417	Ishikawa, Eri	Japan	Prognostic impact of PD-L1 expression, double expressor lymphoma, and progression of disease within 24 months in primary gastrointestinal diffuse large B-cell lymphoma	Publication
418	Lepkov, Sergey	Russian Federation	Impact of different types of antiviral therapy on prognosis of hepatitis C virus positive marginal zone lymphomas	Publication
419	Facchinelli, Davide	Italy	PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE	Publication
420	Wang, Xianhuo	China	Sequential Chemotherapy/Radiotherapy was Superior to Sandwich Therapy for Primary Early-stage DLBCL of Waldeyer's Ring	Publication
421	Xu, Wei	China	Primary thymic mucosa-associated lymphoid tissue lymphoma: 7 clinical cases report and a review of the literature	Publication
422	Salek, David	Czech Republic	First-line adjuvant radiotherapy improves PFS in primary mediastinal large B-cell lymphoma - a retrospective analysis of 102 patients from a single center.	Publication
423	Derenzini, Enrico	Italy	Predictive value of end-of-treatment positron emission tomography scan after DA-EPOCH-R in primary mediastinal B-cell lymphoma. Real-life experience.	Publication
424	Lee, Won Sup	Korea, Republic of	The role of rituximab in primary central nervous system lymphoma (PCNSL): a systematic review and meta-analysis	Publication
425	Bomsztyk, Joshua	United Kingdom	Treatment of Bing Neel Syndrome: Using a sledgehammer to crack a nut?	Publication
426	Bomsztyk, Joshua	United Kingdom	Bing Neel Syndrome: First suspect, then prove - a role for CSF IgM analysis?	Publication
427	Lin, Tongyu	China	A prospective study on the circulation and central nervous system after primary central nervous system B cell lymphoma treatment with Rituximab	Publication
428	Michalka, Jozef	Czech Republic	Frontline therapy results in unselected primary CNS lymphoma patients without consolidation HD chemotherapy followed by autologous stem cell transplantation.	Publication
429	Wasik-Szczepanek, Ewa	Poland	Impact of surgery type on the overall survival time of patients with primary brain lymphoma.	Publication
430	Beltrán, Brady	Peru	PRE-TREATMENT SERUM ALBUMIN LEVEL AS A MEANS OF IMPROVING PROGNOSTIC MODELS IN PERIPHERAL T-CELL LYMPHOMAS: A STUDY FROM THE LATIN AMERICAN GROUP OF LYMPHOMAS (GELL)	Publication
431	Huang, Haiwen	China	Outcome of Autologous Hematopoietic Stem Cell Transplantation in first complete remission in Patients with Low-Risk Peripheral T-Cell Lymphomas (PTCLs)	Publication

432	Gracia Medina, Elias	Cuba	Outcomes in the treatment of patients with T-cell non-Hodgkin's lymphomas. The experience of single institution.	Publication
433	Janikova, Andrea	Czech Republic	T-CELL LYMPHOMA IN THE ELDERLY PATIENTS. WHO IS YOUNG, OLD, AND ELDERLY?	Publication
435	Kim, Seok Jin	Korea, Republic of	Randomized phase II study of CHOP vs. fractionated ICED in transplant-eligible patients with previously untreated peripheral T-cell lymphoma: Interim results of CISL1504	Publication
436	Ogura, Michinori	Japan	A Phase II Study of THP (pirarubicin)-COP therapy in Patients with Newly Diagnosed Advanced PTCL: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group	Publication
437	Shirouchi, Yuko	Japan	Progression free survival at 12 months after first-line therapy is associated with favourable outcomes after first relapse/progression in peripheral T-cell lymphoma.	Publication
438	Jagadeesh, Deepa	United States	Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas	Publication
439	William, Basem	United States	A Phase II Trial of Brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas: Preliminary results of a phase II trial	Publication
440	Ma, Helen	United States	Survival benefit with novel agents in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL): The Columbia University experience.	Publication
441	Lepik, Elena	Russian Federation	Treatment of relapsed and refractory T-cell lymphomas: First Pavlov State Medical University of Saint-Petersburg experience	Publication
442	Marchi, Enrica	United States	Analysis of Published Treatment Options for Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): An Evidence Based Decision Making Approach	Publication
443	Sun, Qian	China	Aggressive NK cell leukemia: clonality, clinical and genetic features	Publication
444	Brammer, Jonatham	United States	Clinical outcomes in patients with Epstein-Barr virus (EBV)-positive non-B cell lymphoma at the Ohio State University James Comprehensive Cancer Center (OSU James CCC)	Publication
445	Ghione, Paola	United States	Treatment and outcomes of patients with NK/T-cell lymphoma treated with modified (m)SMILE and Intensity-Modulated Radiotherapy (IMRT), a single center experience.	Publication
446	Steinerova, Katerina	Czech Republic	Extranodal natural killer (NK)/T-cell lymphoma, nasal type – case report and review of Czech Lymphoma Study Group (CLSG) database.	Publication
447	Fujimoto, Ayumi	Japan	Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Aggressive Natural Killer Cell Leukemia: A Nationwide Multicenter Analysis in Japan	Publication
448	Janakiram, Murali	United States	Updated analysis of genetic sequencing of North American ATLL	Publication
449	Brammer, Jonathan	United States	Clinical Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL) at The Ohio State University James Comprehensive Cancer Center (OSU James-CCC)	Publication

450	Staber, Phillip B.	Austria	The combination of venetoclax and ibrutinib is effective in relapsed/refractory T-prolymphocytic leukemia and influences BCL-2-family member dependencies	Publication
451	Helias, Philippe	France	Adult T-cell Leukemia/Lymphoma : epidemiology, clinical features and outcome of a caribbean cohort from Guadeloupe	Publication
452	Grekova, Ekaterina	Russian Federation	PUVA and interferon α 2b combined therapy for patients with mycosis fungoides: a seven-year retrospective study in Russia	Publication
453	Bagot, Martine	France	Survival among a patient cohort of relapsed/refractory mycosis fungoides in France, Germany, Italy, Spain and the United Kingdom	Publication
454	Svoboda, Jakub	United States	Treatment Patterns, Clinical Outcomes, and Biomarker Evaluation in Classical Hodgkin Lymphoma: A Prospective Observational Study in US Oncology Practices	Publication
455	Aleman, Berthe	Netherlands	Preliminary results of a quality control study on involved node radiotherapy in the EORTC/LYSA/FIL H10 Trial on stages I/II Hodgkin lymphoma	Publication
456	Dalal, Mehul	United States	Clinical outcomes associated with the treatment of newly diagnosed Stage IV classical Hodgkin lymphoma in practice settings in France, Germany, and the United Kingdom	Publication
457	Follows, George	United Kingdom	Modification of escalated BEACOPP with Dacarbazine / Procarbazine substitution reduces red cell transfusion requirements and may shorten time to menstrual period recovery	Publication
458	Tumyan, Gayane	Russian Federation	Updated safety and efficacy results of «HLMoscow 1-3» study for the 147 untreated patients with advanced classical Hodgkin lymphoma	Publication
459	Sibon, David	France	Pooled results of three annual cohorts from an observational prospective study describing brentuximab vedotin use in routine practice in France for Hodgkin Lymphoma: interim analysis	Publication
460	Damlaj, Moussab	Saudi Arabia	Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma	Publication
461	Gaudio, Francesco	Italy	BRENTUXIMAB VEDOTIN PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMAS: A RETROSPECTIVE EXPERIENCE BY THE RETE EMATOLOGICA PUGLIESE (REP).	Publication
462	Mikhailova, Natalia	Russian Federation	Combination of nivolumab and bendamustine in patients with relapsed or refractory classical Hodgkin lymphoma	Publication
463	Lepik, Kirill	Russian Federation	Response to Nivolumab as $\geq 3^{\text{rd}}$ line therapy in pts with relapsed/refractory classical Hodgkin's lymphoma (cHL) and its impact on quality of life in responders and nonresponders	Publication
464	Laliberté, François	Canada	Real-world healthcare resource utilization (HRU) of classical Hodgkin lymphoma (cHL) patients (pts) treated with anti-PD1 checkpoint inhibitors in the United States (US)	Publication

465	Fedorova, Liudmila	Russian Federation	RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS	Publication
466	Chen, Isobel	United Kingdom	Retrospective cohort study to assess the prognostic value of baseline necrosis on PET-CT imaging in Hodgkin lymphoma	Publication
467	Miltényi, Zsófia	Hungary	Prognostic value of pre-transplant PET/CT in Hodgkin lymphoma	Publication
468	Gaudio, Francesco	Italy	MORBIDITY AND MORTALITY IN LONG-TERM SURVIVORS OF HODGKIN LYMPHOMA: A SINGLE CENTER EXPERIENCE	Publication
469	Mocikova, Heidi	Czech Republic	Cognitive impairment after 6 and 12 months of Hodgkin lymphoma treatment	Publication
470	Pinczés, László	Hungary	Impact of autoimmune cytopenias on the clinical course and survival of Hodgkin lymphoma	Publication
471	Strati, Paolo	United States	Relapsed and Refractory Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): a US Analysis from MD Anderson Cancer Center	Publication
472	Rogacheva, Yuliya	Russian Federation	Case series of nivolumab treatment in patients with relapsed/refractory HIV-related lymphomas	Publication
473	Rogacheva, Yuliya	Russian Federation	Infectious complications of nivolumab therapy in relapsed/refractory Hodgkin's lymphoma	Publication
474	Sehgal, Alison	United States	Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (NHL) With Lisocabtagene Maraleucel in the Outpatient Setting: Results from Two Phase 2 Trials	Publication
475	Aftab, Blake	United States	Correlation of circulating Epstein-Barr Virus-targeted Cytotoxic T Lymphocyte Precursors (EBV-CTLp) and clinical response following tacelecleucel (tab-cel) infusion in patients with EBV-driven disease.	Publication
476	Zou, Yi-Xin	China	The roles of PET/CT in predicting the prognosis of chimeric antigen receptor T cell therapy treated patients with diffuse large B cell lymphoma	Publication
477	Avigdor, Abraham	Israel	BASELINE CLINICAL AND PET-CT TUMOR BURDEN PARAMETERS DO NOT PREDICT OUTCOME OF RELAPSE/REFRACTORY AGGRESSIVE B CELL LYMPHOMA PATIENTS TREATED WITH ANTI-CD19 CAR T-CELLS	Publication
478	Jaeger, Ulrich	Austria	Intravenous Immunoglobulin Therapy Use in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel in the JULIET Trial	Publication
479	Shouse, Geoffrey	United States	MDS as a cause for prolonged hematologic toxicity after treatment with CD19 targeted CAR-T cell therapy in patients with relapsed refractory lymphoma	Publication
481	Prieto-García, Laura	Spain	CAR T-CELLS ARE ARRIVING. IS ALLOGENEIC TRANSPLANT AN OBSOLETE APPROACH FOR DE NOVO/TRANSFORMED DLBCL IN THE CAR T-CELLS ERA? LONG-TERM FOLLOW-UP OF A SINGLE CENTRE UNIT	Publication

482	Martinez Calle, Nicolas	United Kingdom	RESULTS OF PHASE II STUDY OF COMBINED IMMUNOTHERAPY WITH RITUXIMAB PLUS LYMPHOKINE-ACTIVATED KILLER CELLS AS MAINTENANCE IN FOLLICULAR LYMPHOMA PATIENTS	Publication
483	Pal, Ipsita	United States	Umbralisib and Carfilzomib Potently Inhibit Cap Dependent Translation in Lymphoma	Publication
484	Till, Kathleen	United Kingdom	Potential therapeutic advantage for duvelisib in Mantle cell lymphoma: PI3K δ and overexpressed PI3K γ in lymphoma cells have specialized functional roles	Publication
485	Booher, Robert	United States	Combination of IRAK4 (CA-4948) and BTK (Vecabrutinib) Inhibitors Show Superior Efficacy in Preclinical Models of ABC DLBCL Tumors Containing MYD88 -L265P Mutations	Publication
486	Spriano, Filippo	Switzerland	Simultaneous BET/CREBBP/EP300 targeting approach compared to single BET or CREBBP/EP300 inhibition in diffuse large B-cell lymphoma (DLBCL)	Publication
487	Gaudio, Eugenio	Switzerland	EG-011 is a novel small molecule with <i>in vitro</i> and <i>in vivo</i> anti-tumor activity against lymphoma	Publication
488	Zhou, Xiangxiang	China	The photosensitizer Verteporfin exerted anti-tumor effect in diffuse large B-cell lymphoma via disrupting YAP-TEAD complex	Publication
489	Alsulami, Hessah	Bahrain	Stem Cells in Acute Lymphoblastic Leukemia and In-Vitro Assessment	Publication
490	Piva, Roberto	Italy	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological	Publication
491	Santos, Carlos	United States	Pre-Clinical Anti-Tumor Activity of a Rapidly-Synthesized Monoclonal Antibody Targeting B-cell Receptor Positive Lymphoma	Publication
492	George, Philip	New Zealand	Third Generation CAR T-cell therapy utilising Toll Like Receptor 2 co-stimulation	Publication
493	Palomba, M. Lia	United States	Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large B-cell lymphoma: primary analysis of a phase 1b study	Publication
494	Lunning, Matthew	United States	A Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma	Publication
495	Querfeld, Christiane	United States	Phase 1/2 trial of anti-PD-Ligand 1 (Durvalumab) +/- Lenalidomide in Patients with Cutaneous T cell Lymphoma: Preliminary Results of Phase 1 and Correlative Studies	Publication
496	Karlsson, Ingrid	Sweden	Phase 1/2a Clinical Trials of BI-1206, a Monoclonal Antibody to Fc γ RIIB, Administered as a Single Agent or in Combination with Rituximab in Subjects with B-cell Malignancies	Publication
497	Jacobson, Caron	United States	A Phase 2 Clinical Trial of Rituximab and β -glucan PGG in Relapsed/Refractory Indolent B-cell Non-Hodgkin Lymphoma	Publication
498	Awan, Farrukh	United States	Treatment Emergent Adverse Events Vary With Different PI3K Inhibitors	Publication
499	Suri, Ajit	United States	Brentuximab vedotin population pharmacokinetic (POPPK) modelling in adult and paediatric patients (pts) with relapsed/refractory (R/R) hematologic malignancies	Publication

500	Janakiram, Murali	United States	Exceptional response of refractory ATLL with MDM4 amplification to novel stapled peptide dual MDM4/2 inhibitor	Publication
501	Samaniego, Felipe	United States	Preliminary Results of ASTX660, a Novel Non-peptidomimetic cIAP1/2 and XIAP Antagonist, in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T cell Lymphoma	Publication
502	Zhang, Mu-chen	China	TitleDecitabine Plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma: Interim Results of a Phase I/II Study	Publication
503	Maakaron, Joseph	United States	Phase I Dose-Escalation Study of Venetoclax plus BEAM followed by Autologous Stem Cell Transplant (ASCT) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (NHL); preliminary results	Publication
504	Mundo, Lucia	Italy	EBV leaves its mark: new evidence of <<hit and run>> hypothesis in B-cell lymphomas from non-conventional methods	Publication
505	Kamal, Muhammad	United States	Single-Center Analysis of Post-transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein Barr Virus (EBV) Assessments.	Publication
506	Rindone, Giovanni	Italy	A RETRO-PROSPECTIVE STUDY IN HIV+ PATIENTS AFFECTED BY LYMPHOMA: THE MUSTHAL MULTICENTER EXPERIENCE IN NORTHERN ITALY	Publication
507	Dalu, Davide	Italy	CHEMOTHERAPY IN HIV-POSITIVE PATIENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY	Publication
508	Xu, Wei	China	Dose-adjusted EPOCH for lymphoma-associated hemophagocytic lymphohistiocytosis: a stone two birds	Publication
509	Bastos-Oreiro, Mariana	Spain	A validation, with new clinical applicability, of a clinical-genetic risk model that predicts thrombosis with high sensitivity in patients with lymphoma	Publication
510	Antic, Darko	Serbia	Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and risk of thromboembolism in patients with lymphoma receiving chemotherapy	Publication
511	Lewis, Katharine	Australia	Clinical outcomes from venetoclax based therapy in patients with relapsed/refractory B-cell lymphomas	Publication
512	Pezzullo, Luca	Italy	Increased cytomegalovirus (CMV) reactivation in patients treated with bendamustine based regimen is correlate with dramatical reduction of CD4+ T lymphocytes	Publication
513	Herbrand, Amanda	Switzerland	Off-label use in lymphoma patients in Switzerland	Publication
514	Bishton, Mark	United Kingdom	CT-P10 RAPID INFUSION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKAEMIA: INTERIM RESULTS FROM A NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY	Publication

515	Dawson, Keith	United States	Patient-reported experience and preferences with treatment of chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)	Publication
516	Matasar, Matthew	United States	Real-world assessment of practice efficiency with the introduction of subcutaneous	Publication
517	Minga, Periana	Italy	GRANISETRON TRANSDERMAL DELIVERY SYSTEM USE IN LYMPHOPROLIFERATIVE DISEASE: A SINGLE CENTER EXPERIENCE.	Publication
518	Prica, Anca	Canada	Functional predictors of chemotherapy toxicity in elderly lymphoma patients – a prospective pilot study	Publication
519	Hadrabova, Marketa	Czech Republic	Is there a role of respiratory training in the supportive care of lymphoma patients? - single centre prospective trial	Publication
520	Warwick, Lorna	Canada	A cross-sectional study examining how knowledge of lymphoma subtype affects the patient experience	Publication
521	Bersvendsen, Hanne	Norway	Reduced sexual function in long-term male lymphoma survivors after high dose therapy with autologous stem cell transplantation	Publication
522	Prica, Anca	Canada	Quality of life and caregiver burden in multiple myeloma and lymphoma patients undergoing outpatient autologous stem cell transplantation versus inpatient transplantation	Publication
523	Hadrabova, Marketa	Czech Republic	SYMPATHOVAGAL IMBALANCE IN LYMPHOMA PATIENTS CAN BE RESTORED BY PHYSICAL TRAINING - single centre prospective trial	Publication
524	Vales, Karel	Czech Republic	Lymphoma treatment regimes and their impact on behaviour and cognition in an animal model	Publication
525	MacManus, Michael	Australia	Abscopal regression of lymphoma at distant sites after local radiotherapy, detected by Positron Emission Tomography in six cases	Publication
526	Teoh, Phaik Ju	Singapore	Aberrant hyperediting of myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis	Publication
527	Czyz, Anna	Poland	Autologous stem cell transplant with high dose melphalan preparative regimen is safe and effective for elderly multiple myeloma patients in the era of triple induction therapy	Publication
528	Garifullin, Andrey	Russian Federation	The use modified risk stratification mSMART 3.0 in real clinic practice in patients with newly diagnosed multiple myeloma	Publication
529	Gmati, Giamal Edin	Saudi Arabia	Outcome of Autologous Stem Cell Transplantation in Multiple Myeloma; Experience from a Single Center in Saudi Arabia	Publication
530	Garifullin, Andrey	Russian Federation	The role of autologous stem cell transplantation and tumor load in multiple myeloma	Publication
OT07	Wang, Michael	United States	A Phase 3 Study of Acalabrutinib Plus Bendamustine and Rituximab in Elderly (Aged ≥65 Years) Treatment-Naive Patients With Mantle Cell Lymphoma	Publication

OT08	Davies, Andrew	United Kingdom	ARGO: A randomised phase II study of atezolizumab with rituximab, gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for high-dose therapy.	Publication
OT09	Zelenetz, Andrew	United States	A Pivotal, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Two Dosing Schedules in Patients with Follicular Lymphoma (FL) After Failure of Two or More Prior Systemic Therapies	Publication
OT10	Chiappella, Annalisa	Italy	Phase II FIL-PTCL13 Study of Romidepsin-CHOEP Followed by High-Dose Chemotherapy and Transplantation in Untreated Peripheral T-cell Lymphomas	Publication
OT11	Montillo, Marco	Italy	A multicenter, open label, uncontrolled, phase II trial evaluating safety and efficacy of venetoclax, atezolizumab and obinutuzumab in Richter transformation from CLL.	Publication
OT12	Minard-Colin, Veronique	France	BIANCA: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma	Publication
OT13	Dickinson, Michael	Australia	ELARA: A Phase 2 Trial Investigating the Efficacy and Safety of Tisagenlecleucel in Adult Patients with Refractory/Relapsed Follicular Lymphoma	Publication
OT14	Jaeger, Ulrich	Austria	PORTIA: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	Publication
OT15	Ruan, Jia	United States	Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma	Publication
OT16	Younes, Anas	United States	Dose Finding Study to Assess Safety, PK and Efficacy of Fimepinostat (CUDC-907) with Venetoclax or Rituximab plus Bendamustine in Patients with Relapsed/Refractory Lymphoma	Publication
OT17	James, Adam	United States	SOLAR: A Phase 2, Global, Randomized, Active Comparator Study to Investigate the Efficacy and Safety of cobomarsen in Subjects with Mycosis Fungoides (MF)	Publication
OT18	Mobasher, Mehrdad	United States	A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma	Publication
OT19	Budde, Lihua	United States	Ongoing phase 1b/2 trials of mosunetuzumab investigating novel treatment regimens for patients with B-cell non-Hodgkin lymphoma (NHL)	Publication
OT20	Burnett, Christine	United States	A Phase 1/2 Study of MT-3724 to evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma	Publication
OT21	Popplewell, Leslie	United States	A First-in-Human Study of a Half-Life Extended CD19-targeting BiTE in Relapsed/Refractory Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma	Publication

OT22	Kim, Wonseog	Korea, Republic of	An ongoing phase 1/1b trial investigating novel treatment regimens with mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma	Publication
OT23	Berinstein, Neil	Canada	SPiReL: Phase 2 Study DPX-Survivac with Intermittent Low Dose Cyclophosphamide and Pembrolizumab in Patients with recurrent/refractory Diffuse Large B-Cell Lymphoma	Publication
OT24	Ujjani, Chaitra	United States	Phase Ib/II Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular	Publication
OT25	Graf, Solomon	United States	A Window Study of Ixazomib in Untreated B-NHL	Publication
OT26	Canales, Miguel	Spain	Ongoing study of obinutuzumab short duration infusion in patients with previously untreated advanced follicular lymphoma	Publication
OT27	Melén, Christopher	Sweden	The Cannabinoidstudy – 01: Investigating the effects of cannabinoids in indolent leukemic B-cell lymphoma	Publication
OT28	Lynch, Ryan	United States	A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for patients with Untreated Classical Hodgkin Lymphoma	Publication
OT29	Svoboda, Jakub	United States	EVITA: Phase I/II Study of Everolimus plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma	Publication
OT30	Macklin-Doherty, Aislinn	United Kingdom	UK: National cohort study investigating major late effects of Hodgkin Lymphoma treatments On behalf of the England & Wales Hodgkin Lymphoma Follow-up Group	Publication